Clinical

Dataset Information

0

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor


ABSTRACT: This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors likely to exhibit elevated levels of Epidermal Growth Factor Receptor (EGFR).

DISEASE(S): Colorectal Carcinoma,Squamous Cell Carcinoma Of Head And Neck,Glioblastoma Multiforme,Carcinoma,Triple Negative Breast Neoplasms,Glioblastoma,Non-small Cell Lung Cancer,Colorectal Neoplasms,Triple Negative Breast Cancer,Head And Neck Squamous Cell Carcinoma,Solid Tumors,Cancer

PROVIDER: 2184006 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-09-02 | GSE182994 | GEO
2023-12-15 | GSE249023 | GEO
2023-12-15 | GSE249542 | GEO
2017-03-07 | GSE89934 | GEO
2020-04-06 | PXD016166 | Pride
2017-03-07 | GSE89933 | GEO
2017-03-07 | GSE89935 | GEO
| 2235325 | ecrin-mdr-crc
2021-01-31 | GSE144326 | GEO
| 2295725 | ecrin-mdr-crc